Imaging-Derived Biomarkers Integrated with Clinical and Laboratory Values Predict Recurrence of Hepatocellular Carcinoma After Liver Transplantation

References

• Liver EAFTSOT. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13(1):e11–22. doi:10.1016/S1470-2045(11)70175-9
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17(Suppl 2):S44–57. doi:10.1002/lt.22365
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol. 2020;21(7):947–956. doi:10.1016/S1470-2045(20)30224-2
   PubMed Web of Science ®Google Scholar
• Yao FY. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–1403. doi:10.1053/jhep.2001.24563
   PubMed Web of Science ®Google Scholar
• Toso C, Asthana S, Bigam DL, Shapiro AJ, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology. 2009;49(3):832–838. doi:10.1002/hep.22693
   PubMed Web of Science ®Google Scholar
• Morgul MH, Felgendreff P, Kienlein A, et al. Milan criteria in the MELD era-is it justifiable to extend the limits for orthotopic liver transplantation? World J Surg Oncol. 2020;18(1):158. doi:10.1186/s12957-020-01932-6
   PubMed Web of Science ®Google Scholar
• Pommergaard H-C, Rostved AA, Adam R, et al. Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European liver transplant registry. Hpb. 2018;20(8):768–775. doi:10.1016/j.hpb.2018.03.002
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, Choti MA. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg. 2007;245(3):435–442. doi:10.1097/01.sla.0000250420.73854.ad
   PubMed Web of Science ®Google Scholar
• Kim AY, Sinn DH, Jeong WK, et al. Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma. J Hepatol. 2018;68(6):1144–1152. doi:10.1016/j.jhep.2018.01.024
   PubMed Web of Science ®Google Scholar
• Lee S, Kim SH, Lee JE, Sinn DH, Park CK. Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. J Hepatol. 2017;67(3):526–534. doi:10.1016/j.jhep.2017.04.024
   PubMed Web of Science ®Google Scholar
• Ivanics T, Salinas-Miranda E, Abreu P, et al. A pre-TACE radiomics model to predict HCC progression and recurrence in liver transplantation: a pilot study on a novel biomarker. Transplantation. 2021;105(11):2435–2444. doi:10.1097/TP.0000000000003605
   PubMed Web of Science ®Google Scholar
• Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289(3):816–830. doi:10.1148/radiol.2018181494
   PubMed Web of Science ®Google Scholar
• Öcal O, Ingrisch M, Ümütlü MR, et al. Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma. Br J Cancer. 2022;126(2):211–218. doi:10.1038/s41416-021-01577-6
   PubMed Web of Science ®Google Scholar
• Kim H, Park MS, Choi JY, et al. Can microvessel invasion of hepatocellular carcinoma be predicted by pre-operative MRI? Eur Radiol. 2009;19(7):1744–1751. doi:10.1007/s00330-009-1331-8
   PubMed Web of Science ®Google Scholar
• Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137(3):850–855. doi:10.1053/j.gastro.2009.06.003
   PubMed Web of Science ®Google Scholar
• Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7(11):2587–2596. doi:10.1111/j.1600-6143.2007.01965.x
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43. doi:10.1016/S1470-2045(08)70284-5
   PubMed Web of Science ®Google Scholar
• Yang SH, Suh KS, Lee HW, et al. A revised scoring system utilizing serum alpha fetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery. 2007;141(5):598–609. doi:10.1016/j.surg.2006.11.006
   PubMed Web of Science ®Google Scholar
• Costentin C, Piñero F, Degroote H, et al. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. JHEP Rep. 2022;4(5):100445. doi:10.1016/j.jhepr.2022.100445
   PubMedGoogle Scholar
• Hack SP, Spahn J, Chen M, et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol. 2020;16(15):975–989. doi:10.2217/fon-2020-0162
   PubMed Web of Science ®Google Scholar
• Kim BK, Kim KA, An C, et al. Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. Liver Int. 2015;35(6):1722–1730. doi:10.1111/liv.12751
   PubMed Web of Science ®Google Scholar
• Kim KA, Kim MJ, Jeon HM, et al. Prediction of microvascular invasion of hepatocellular carcinoma: usefulness of peritumoral hypointensity seen on gadoxetate disodium-enhanced hepatobiliary phase images. J Magn Reson Imaging. 2012;35(3):629–634. doi:10.1002/jmri.22876
   PubMed Web of Science ®Google Scholar
• Renzulli M, Brocchi S, Cucchetti A, et al. Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? Radiology. 2016;279(2):432–442. doi:10.1148/radiol.2015150998
   PubMed Web of Science ®Google Scholar
• Tan PS, Nakagawa S, Goossens N, et al. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int. 2016;36(1):108–118. doi:10.1111/liv.12889
   PubMed Web of Science ®Google Scholar
• Nishioka ST, Sato MM, Wong LL, Tiirikainen M, Kwee SA. Clinical and molecular sub-classification of hepatocellular carcinoma relative to alpha-fetoprotein level in an Asia-Pacific island cohort. Hepatoma Res. 2018;4:4. doi:10.20517/2394-5079.2017.50
   PubMedGoogle Scholar
• Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018;154(1):128–139. doi:10.1053/j.gastro.2017.09.025
   PubMed Web of Science ®Google Scholar